Cancer Channel
Related Channels

Alemtuzumab Dosage

As you begin treatment with alemtuzumab, dosing will start at 3 mg a day and will be increased based on how well you tolerate it. This drug is given intravenously every other day, 3 times a week, for 12 weeks. The full recommended dosage is 30 mg. Your healthcare provider will give you special drugs before the infusion to reduce the risk of potentially serious reactions.

An Introduction to Your Dosage of Alemtuzumab

The dose of alemtuzumab (Campath®) your healthcare provider recommends will vary, depending on how well you tolerate the medication. As is always the case, do not adjust your dosage unless your healthcare provider specifically tells you to do so.

Alemtuzumab Dosing Guidelines

The standard recommended dosage of alemtuzumab for the treatment of leukemia is 30 mg a day, every other day, 3 times a week, for 12 weeks. However, the medication is started at a much lower dose and slowly increased to this recommended amount. This allows the body time to adjust to the medicine.
Therefore, the recommended initial dosage of alemtuzumab is 3 mg per day, until serious side effects do not occur. The amount is then increased to 10 mg per day. Once this amount is tolerated without serious side effects, the dose will be increased to the recommended 30 mg.
The total duration of treatment is 12 weeks. Most people will reach the 30-mg dose within three to seven days of starting alemtuzumab.
Medications such as diphenhydramine (Benadryl®) 50 mg and acetaminophen (Tylenol®) 500 to 1000 mg are normally given 30 minutes before the first alemtuzumab dose and with each increase. These help reduce the risk of an infusion reaction (a serious reaction to the medication that may occur during or shortly after receiving the dose).
In addition, anti-infective medications, such as antibiotics and antifungal medications, will be given during treatment and for at least two months after treatment ends. This helps prevent certain serious infections from occurring.
5 Easy Tips to Manage Visitors During Cancer Treatment

Alemtuzumab Drug Information

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2019 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.